New 2,000 IU vial size for Bayer's Kogenate
German pharmaceutical major Bayer HealthCare has announced the availability of a new 2,000 IU (international unit) vial size in the USA for hemophilia A patients treated with Kogenate (Factor VIII) FS, Antihemophilic Factor (Recombinant), and Kogenate FS Antihemophilic Factor (recombinant), with BIO-SET, a needleless reconstitution system.
The 2,000 IU vial size reduces reconstitution time by eliminating the need to mix and pool multiple vials for some patients requiring higher doses. The increased capacity also includes a new one-cut stopper and vial designed to simplify handling of reconstituted Kogenate FS.
"By reducing reconstitution time, the new 2,000 IU vial size aims to make it easier for patients to be compliant with their prescribed treatment," says Terry Tenbrunsel, vice president, sales and marketing, Bayer HealthCare in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze